Detalles de la búsqueda
1.
First-in-Human Phase I Study of Envafolimab, a Novel Subcutaneous Single-Domain Anti-PD-L1 Antibody, in Patients with Advanced Solid Tumors.
Oncologist
; 26(9): e1514-e1525, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-33973293
2.
A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179.
Cancer
; 126(19): 4353-4361, 2020 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32697352
3.
Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.
Oncologist
; 24(8): 1095-1102, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-30975923
4.
CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma.
Blood
; 127(26): 3360-8, 2016 06 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-27207788
5.
A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma.
Am J Hematol
; 92(5): 460-466, 2017 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-28213943
6.
A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma.
Ann Hematol
; 93(1): 89-98, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-24135804
7.
Results from phase 1 of the MANIFEST clinical trial to evaluate the safety and tolerability of pelabresib in patients with myeloid malignancies.
Leuk Lymphoma
; 65(4): 503-510, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38259250
8.
First-in-human phase I dose escalation trial of the first-in-class tumor microenvironment modulator VT1021 in advanced solid tumors.
Commun Med (Lond)
; 4(1): 10, 2024 Jan 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-38218979
9.
Safety and efficacy of the tumor-selective adenovirus enadenotucirev, in combination with nivolumab, in patients with advanced/metastatic epithelial cancer: a phase I clinical trial (SPICE).
J Immunother Cancer
; 11(4)2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37094988
10.
Safety and Efficacy of a DNA Oligonucleotide Therapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Clin Lymphoma Myeloma Leuk
; 22(1): 52-59, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34454850
11.
Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia.
Haematologica
; 101(7): e295-8, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27151992
12.
A Phase 2 Study of PNT2258 for Treatment of Relapsed or Refractory B-Cell Malignancies.
Clin Lymphoma Myeloma Leuk
; 21(12): 823-830, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34417162
13.
Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies.
Target Oncol
; 16(4): 461-469, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33939067
14.
Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer.
J Clin Oncol
; 39(12): 1360-1370, 2021 04 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-33513026
15.
Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies.
Clin Cancer Res
; 26(6): 1247-1257, 2020 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31527168
16.
An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study.
Lancet Haematol
; 6(4): e194-e203, 2019 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-30926081
17.
A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors.
Oncotarget
; 9(60): 31709-31718, 2018 Aug 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30167089
18.
Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders.
Clin Cancer Res
; 24(22): 5525-5533, 2018 11 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-29844129
19.
A Multicenter, Open-Label, Phase 1b Study of Carfilzomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients (CHAMPION-2).
Clin Lymphoma Myeloma Leuk
; 17(7): 433-437, 2017 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-28576443
20.
Radiation binary targeted therapy for HER-2 positive breast cancers: assumptions, theoretical assessment and future directions.
Phys Med Biol
; 51(6): 1377-91, 2006 Mar 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-16510950